Figure S1



Figure S1. EMT is induced and quisinostat reverts EMT in the osimertinib resistant H1975-bulk cells. (A) H1975 parental and the H1975OR-bulk were evaluated to determine any morphologic changes consistent with EMT using light microscope. Scale bar = 200 μm. (B) The expression of EMT markers were analyzed by western blot using the indicated antibodies. (C) Relative expression of miR-200c was measured in H1975 parental and H1975OR-bulk cells (n=3). Error bars represent the SEM and * indicates $p<0.05$. (D)H1975-resistant clone cells were treated with miR-200c mimic. The change of ZEB1 and E-cadherin expression were determined by western blot analysis. (E) Change in the expression of ZEB1 and E-cadherin in H1975OR-bulk cells treated with 0.03 μM quisinostat was determined by western blot analysis. (E) H1975OR-bulk cells were pre-treated with 0.03 μM quisinostat for 48 h, followed by treatment with osimertinib for 72 h. Cell viability was measured using the MTT assay (n=3).

Figure S2



Figure S2. The effect of HDAC inhibitors on the reversion of EMT in osimertinib-reisisitant H1975 clones. The change in the expression of ZEB1 and E-cadherin in the resistant clones treated with 1μM of the HDAC inhibitors were determined by western blot analysis.



Figure S3. Effect of silencing of ZEB1 or Slug on the change in EMT. (A) The change of EMT markers in the resistant clones treated for 72 h with si-ZEB1 or si-Slug was determined by western blot analysis. (B) The change of cell shape in the resistant clones treated with si-ZEB1 or si-Slug for 72h was analyzed by light microscopy.



Figure S4. The effect of GSK-3 inhibitors in H1975-OR#3 cells. OR#3 cells were treated with 1 μM of the GSK inhibitors for 72h. Cell viability was measured using the MTT assay (n=3) .



Figure S5. Wnt/β-catenin signaling pathway is not activated in the osimertinib-reisisitant H1975 clones. (A) The expression of β-catenin in the cytosol and nucleus was determined by western blot analysis.（B)The expression and phospholylation of GSKα/β, and the expression of β-catenin were determined by western blot analysis with the indicated antibodies.